Comparative Pharmacology
Head-to-head clinical analysis: DROPERIDOL versus SONAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROPERIDOL versus SONAZINE.
DROPERIDOL vs SONAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droperidol is a butyrophenone antipsychotic that acts primarily as a dopamine D2 receptor antagonist. It also exhibits antiemetic effects via blockade of dopamine D2 receptors in the chemoreceptor trigger zone. Additionally, it has alpha-adrenergic blocking properties and can prolong the QT interval by blocking cardiac potassium channels (hERG).
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
2.5-10 mg IV/IM every 3-4 hours as needed for nausea and vomiting; for agitation or psychosis in perioperative settings: 0.625-1.25 mg IV/IM, may repeat every 6 hours.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderateDroperidol + Norfloxacin
"Droperidol may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDroperidol + Ibandronate
"Droperidol may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateDroperidol + Indapamide
"Droperidol may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateDroperidol + Methylphenidate
"The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate."
Terminal elimination half-life: 2.3 hours (range 1.5–4.7 hours). Clinical context: Short half-life allows rapid titration but requires repeated dosing or continuous infusion for sustained effect; accumulation with hepatic impairment.
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Renal (75% as metabolites, <1% unchanged); fecal (22%); biliary excretion contributes to enterohepatic circulation.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Category A/B
Category C
Antipsychotic
Antipsychotic